World Alzheimer Day: Notable Clinical Interviews From 2026

Observed annually on September 21, World Alzheimer's Day provides an opportunity to raise awareness of Alzheimer disease (AD), recognize the challenges faced by patients and caregivers, and highlight ongoing efforts to improve diagnosis, treatment, and understanding of the disease. As the clinical and research landscape of AD continues to evolve, advances in biomarker development, artificial intelligence, and disease-modifying therapies are generating new questions about how the disease is detected, characterized, and managed.

New research into blood-based biomarkers such as p-tau217, deep learning models for predicting disease progression, and approaches to identifying Alzheimer pathology in individuals with Down syndrome reflects the continued effort to improve diagnostic precision and better understand disease biology. At the same time, investigations into the mechanisms underlying neurodegeneration, the effects of anti-amyloid therapies, and the management of Alzheimer disease–associated agitation highlight the range of challenges clinicians and researchers continue to address.

Throughout 2026, NeurologyLive® spoke with experts about several of these developments, examining the study designs behind emerging biomarker approaches, the potential clinical applications of new diagnostic technologies, and the research shaping our understanding of Alzheimer disease across different patient populations.

In recognition of World Alzheimer's Day, this roundup revisits 8 expert conversations from the year, highlighting perspectives on biomarkers, treatment advances, disease mechanisms, clinical research, and the ongoing challenges of translating scientific findings into patient care. Together, these discussions offer insight into the questions shaping the field and the developments that may inform future approaches to AD diagnosis and management.